Alzheimer’s disease

Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in ​Mild-to-Moderate AD Patients​

Hamby ME, Kavanagh S, Di Caro V, et al. Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in ​Mild-to-Moderate AD Patients​. Poster presented at AD/PD 2025; Vienna, Austria

Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in ​Mild-to-Moderate AD Patients​ Read More »

Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease

Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria

Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease Read More »

Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease: Focus on Pre-specified Lower p-tau217 Subgroup

Woodward M, Vijverberg EGB, Di Caro V, et al. Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease: Focus on Pre-specified Lower p-tau217 Subgroup. Slides presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2024; Madrid, Spain

Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease: Focus on Pre-specified Lower p-tau217 Subgroup Read More »

CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer’s disease

Lizama BN, Willaims C, North HA, et al. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer’s disease. Alzheimer’s Dement. 2024; 1-21.

CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer’s disease Read More »

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org